Apimeds Pharmaceuticals US, Inc.
APUS
$2.21
$0.178.33%
AMEX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 452.17% | 32.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 631.04% | 32.22% | |||
| Operating Income | -631.04% | -32.22% | |||
| Income Before Tax | -561.58% | -29.14% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -561.58% | -29.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -561.58% | -29.14% | |||
| EBIT | -631.04% | -32.22% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -404.32% | -29.19% | |||
| Normalized Basic EPS | -404.72% | -29.27% | |||
| EPS Diluted | -404.32% | -29.19% | |||
| Normalized Diluted EPS | -404.72% | -29.27% | |||
| Average Basic Shares Outstanding | 31.19% | 0.00% | |||
| Average Diluted Shares Outstanding | 31.19% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||